Barclays Raises Valeant Pharmaceuticals' Price Target By: Benzinga via Benzinga January 09, 2015 at 16:35 PM EST Barclays raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $149 to $179 Friday and maintained a Buy ... Read More >> Related Stocks: Cross Timbers Royalty Trust Valeant Pharmaceuticals International, Inc.